Natco Pharma

Natco Pharma
Type	Public company
Traded as	NSE: NATCOPHARM ; BSE: 524816
Industry	Pharmaceuticals
Founded	1981
Founders	VC Nannapaneni
Headquarters	Hyderabad, India
Area served	Global
Key people	VC Nannapaneni (Chairman and MD)[1]; Rajeev Nannapaneni (CEO and Vice Chairman)[2]
Website	natcopharma.co.in

Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India,[3] and among the country's top three producers of hepatitis C drugs.[4]

In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[5] In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[4] In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[6]

In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[5]

References

"Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
"Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
"Natco Pharma lines up 20 `Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
"How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
"Niche Play". Business Today. Retrieved 19 April 2020.
"Natco Pharma launches blood cancer drug priced Rs 5,000-20,000, down 98% from US price - Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.

[2] "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.

[paraiv-3] "Natco Pharma lines up 20 `Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.

[ladder-4] "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.

[niche-5] "Niche Play". Business Today. Retrieved 19 April 2020.

[6] "Natco Pharma launches blood cancer drug priced Rs 5,000-20,000, down 98% from US price - Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.